03141nas a2200313   4500008004100000245013000041210006900171300001200240490000700252520169500259653011401954653003602068653016902104653009402273653012702367100002202494700002602516700001402542700001602556700003002572700001702602700001702619700002002636700001502656700001702671700001602688700001702704856010602721       2008                        eng d00aMolecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information0 aMolecular profiling related to poor prognosis in thyroid carcino  a1554-610 v273 a<p>Undifferentiated and poorly differentiated thyroid tumors are responsible for more than half of thyroid cancer patient deaths in spite of their low incidence. Conventional treatments do not obtain substantial benefits, and the lack of alternative approaches limits patient survival. Additionally, the absence of prognostic markers for well-differentiated tumors complicates patient-specific treatments and favors the progression of recurrent forms. In order to recognize the molecular basis involved in tumor dedifferentiation and identify potential markers for thyroid cancer prognosis prediction, we analysed the expression profile of 44 thyroid primary tumors with different degrees of dedifferentiation and aggressiveness using cDNA microarrays. Transcriptome comparison of dedifferentiated and well-differentiated thyroid tumors identified 1031 genes with &gt;2-fold difference in absolute values and false discovery rate of &lt;0.15. According to known molecular interaction and reaction networks, the products of these genes were mainly clustered in the MAPkinase signaling pathway, the TGF-beta signaling pathway, focal adhesion and cell motility, activation of actin polymerization and cell cycle. An exhaustive search in several databases allowed us to identify various members of the matrix metalloproteinase, melanoma antigen A and collagen gene families within the upregulated gene set. We also identified a prognosis classifier comprising just 30 transcripts with an overall accuracy of 95%. These findings may clarify the molecular mechanisms involved in thyroid tumor dedifferentiation and provide a potential prognosis predictor as well as targets for new therapies.</p>10aAdenoma/genetics/metabolism/pathology Adolescent Adult Aged Carcinoma/genetics/metabolism/pathology Carcinoma10aBiological/*genetics/metabolism10aNeoplasm/genetics/metabolism Reverse Transcriptase Polymerase Chain Reaction Signal Transduction Thyroid Neoplasms/classification/*genetics/metabolism Tumor Markers10aNeoplastic Humans Male Middle Aged *Oligonucleotide Array Sequence Analysis Prognosis RNA10aPapillary/genetics/metabolism/pathology Cell Differentiation Female *Gene Expression Profiling *Gene Expression Regulation1 aMontero-Conde, C.1 aMartin-Campos, J., M.1 aLerma, E.1 aGimenez, G.1 aMartinez-Guitarte, J., L.1 aCombalia, N.1 aMontaner, D.1 aMatias-Guiu, X.1 aDopazo, J.1 ade Leiva, A.1 aRobledo, M.1 aMauricio, D.  uhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1787390803226nas a2200433   4500008004100000245012400041210006900165300001100234490000700245520156900252653002601821653003101847653001201878653013601890653023502026653003902261100002202300700002202322700001802344700001702362700001602379700001402395700001502409700001902424700001402443700001602457700002402473700002302497700002302520700001802543700001602561700002302577700001602600700002002616700001502636700001902651700001602670856010602686       2007                        eng d00aAssociation study of 69 genes in the ret pathway identifies low-penetrance loci in sporadic medullary thyroid carcinoma0 aAssociation study of 69 genes in the ret pathway identifies lowp  a9561-70 v673 aTo date, few association studies have been done to better understand the genetic basis for the development of sporadic medullary thyroid carcinoma (sMTC). To identify additional low-penetrance genes, we have done a two-stage case-control study in two European populations using high-throughput genotyping. We selected 417 single nucleotide polymorphisms (SNP) belonging to 69 genes either related to RET signaling pathway/functions or involved in key processes for cancer development. TagSNPs and functional variants were included where possible. These SNPs were initially studied in the largest known series of sMTC cases (n = 266) and controls (n = 422), all of Spanish origin. In stage II, an independent British series of 155 sMTC patients and 531 controls was included to validate the previous results. Associations were assessed by an exhaustive analysis of individual SNPs but also considering gene- and linkage disequilibrium-based haplotypes. This strategy allowed us to identify seven low-penetrance genes, six of them (STAT1, AURKA, BCL2, CDKN2B, CDK6, and COMT) consistently associated with sMTC risk in the two case-control series and a seventh (HRAS) with individual SNPs and haplotypes associated with sMTC in the Spanish data set. The potential role of CDKN2B was confirmed by a functional assay showing a role of a SNP (rs7044859) in the promoter region in altering the binding of the transcription factor HNF1. These results highlight the utility of association studies using homogeneous series of cases for better understanding complex diseases.10a80 and over Carcinoma10aAdolescent Adult Aged Aged10aGenetic10aGenetic Proto-Oncogene Proteins c-ret/*genetics/metabolism Signal Transduction Thyroid Neoplasms/*genetics/metabolism Transcription10aMedullary/*genetics/metabolism Case-Control Studies Cyclin-Dependent Kinase Inhibitor p15/biosynthesis/genetics Female Genetic Predisposition to Disease Germ-Line Mutation Haplotypes Humans Male Middle Aged Penetrance Polymorphism10aSingle Nucleotide Promoter Regions1 aRuiz-Llorente, S.1 aMontero-Conde, C.1 aMilne, R., L.1 aMoya, C., M.1 aCebrian, A.1 aLeton, R.1 aCascon, A.1 aMercadillo, F.1 aLanda, I.1 aBorrego, S.1 ade Nanclares, Perez1 aAlvarez-Escola, C.1 aDiaz-Perez, J., A.1 aCarracedo, A.1 aUrioste, M.1 aGonzalez-Neira, A.1 aBenitez, J.1 aSantisteban, P.1 aDopazo, J.1 aPonder, B., A.1 aRobledo, M.  uhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1790906700519nas a2200121   4500008004100000245007600041210006900117260004900186100001600235700002300251700001500274856010800289       2007                        eng d00af single nucleotide polymorphism arrays: Design, tools and applications0 af single nucleotide polymorphism arrays Design tools and applica  aNew York, USAbTaylor & Francis, F. Falciani1 aRobledo, M.1 aGonzález-Neira, A1 aDopazo, J.  uhttp://clinbioinfosspa.es/content/f-single-nucleotide-polymorphism-arrays-design-tools-and-applications02830nas a2200277   4500008004100000245011000041210006900151300001100220490000700231520162300238653016301861653002002024653018602044653004602230100001802276700001402294700002302308700001802331700001402349700001702363700001502380700001902395700001602414700001602430856010602446       2006                        eng d00aERCC4 associated with breast cancer risk: a two-stage case-control study using high-throughput genotyping0 aERCC4 associated with breast cancer risk a twostage casecontrol   a9420-70 v663 aThe failure of linkage studies to identify further high-penetrance susceptibility genes for breast cancer points to a polygenic model, with more common variants having modest effects on risk, as the most likely candidate. We have carried out a two-stage case-control study in two European populations to identify low-penetrance genes for breast cancer using high-throughput genotyping. Single-nucleotide polymorphisms (SNPs) were selected across preselected cancer-related genes, choosing tagSNPs and functional variants where possible. In stage 1, genotype frequencies for 640 SNPs in 111 genes were compared between 864 breast cancer cases and 845 controls from the Spanish population. In stage 2, candidate SNPs identified in stage 1 (nominal P < 0.01) were tested in a Finnish series of 884 cases and 1,104 controls. Of the 10 candidate SNPs in seven genes identified in stage 1, one (rs744154) on intron 1 of ERCC4, a gene belonging to the nucleotide excision repair pathway, was associated with recessive protection from breast cancer after adjustment for multiple testing in stage 2 (odds ratio, 0.57; Bonferroni-adjusted P = 0.04). After considering potential functional SNPs in the region of high linkage disequilibrium that extends across the entire gene and upstream into the promoter region, we concluded that rs744154 itself could be causal. Although intronic, it is located on the first intron, in a region that is highly conserved across species, and could therefore be functionally important. This study suggests that common intronic variation in ERCC4 is associated with protection from breast cancer.10a80 and over Breast Neoplasms/epidemiology/*genetics/pathology Case-Control Studies DNA-Binding Proteins/genetics/*physiology Female Finland/epidemiology Genes10aAdult Aged Aged10aRecessive Genetic Predisposition to Disease Genotype Humans Introns/genetics Linkage Disequilibrium Middle Aged Neoplasm Proteins/genetics/*physiology Neoplasm Staging *Polymorphism10aSingle Nucleotide Risk Spain/epidemiology1 aMilne, R., L.1 aRibas, G.1 aGonzalez-Neira, A.1 aFagerholm, R.1 aSalas, A.1 aGonzalez, E.1 aDopazo, J.1 aNevanlinna, H.1 aRobledo, M.1 aBenitez, J.  uhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1701859602687nas a2200337   4500008004100000245010400041210006900145300001000214490000700224520138200231653003401613653006501647653002501712653001001737653003201747653003301779653003201812653019101844100001502035700002202050700002602072700001602098700002502114700001402139700002202153700001602175700001502191700002102206700001602227856010602243       2005                        eng d00aA novel candidate region linked to development of both pheochromocytoma and head/neck paraganglioma0 anovel candidate region linked to development of both pheochromoc  a260-80 v423 aAlthough the histologic distinction between pheochromocytomas and head and neck paragangliomas is clear, little is known about the genetic differences between them. To date, various sets of genes have been found to be involved in inherited susceptibility to developing both tumor types, but the genes involved in sporadic pathogenesis are still unknown. To define new candidate regions, we performed CGH analysis on 29 pheochromocytomas and on 24 paragangliomas mainly of head and neck origin (20 of 24), which allowed us to differentiate between the two tumor types. Loss of 3q was significantly more frequent in pheochromocytomas, and loss of 1q appeared only in paragangliomas. We also found gain of 11q13 to be a significantly frequent alteration in malignant cases of both types. In addition, recurrent loss of 8p22-23 was found in 62% of pheochromocytomas (including all malignant cases) versus in 33% of paragangliomas, suggesting that this region contains candidate genes involved in the pathogenesis of this abnormality. Using FISH analysis on tissue microarrays, we confirmed genomic deletion of this region in 55% of pheochromocytomas compared to 12% of paragangliomas. Loss of 8p22-23 appears to be an important event in the sporadic development of these tumors, and additional molecular studies are necessary to identify candidate genes in this chromosomal region.10a80 and over Child Chromosomes10aAdolescent Adrenal Gland Neoplasms/*genetics Adult Aged Aged10aBiological/*genetics10aHuman10aPair 1/genetics Chromosomes10aPair 11/genetics Chromosomes10aPair 3/genetics Chromosomes10aPair 8/genetics Female Gene Deletion Head and Neck Neoplasms/*genetics Humans Male Middle Aged Nucleic Acid Hybridization Paraganglioma/*genetics Pheochromocytoma/*genetics Tumor Markers1 aCascon, A.1 aRuiz-Llorente, S.1 aRodriguez-Perales, S.1 aHonrado, E.1 aMartinez-Ramirez, A.1 aLeton, R.1 aMontero-Conde, C.1 aBenitez, J.1 aDopazo, J.1 aCigudosa, J., C.1 aRobledo, M.  uhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1560934702164nas a2200229   4500008004100000245009400041210006900135300001100204490000700215520128900222653008201511653001201593653009301605100001401698700002301712700001601735700002401751700002201775700001601797700001501813856010601828       2004                        eng d00aPupaSNP Finder: a web tool for finding SNPs with putative effect at transcriptional level0 aPupaSNP Finder a web tool for finding SNPs with putative effect   aW242-80 v323 aWe have developed a web tool, PupaSNP Finder (PupaSNP for short), for high-throughput searching for single nucleotide polymorphisms (SNPs) with potential phenotypic effect. PupaSNP takes as its input lists of genes (or generates them from chromosomal coordinates) and retrieves SNPs that could affect the conserved regions that the cellular machinery uses for the correct processing of genes (intron/exon boundaries or exonic splicing enhancers), predicted transcription factor binding sites (TFBS) and changes in amino acids in the proteins. The program uses the mapping of SNPs in the genome provided by Ensembl. Additionally, user-defined SNPs (not yet mapped in the genome) can be easily provided to the program. Also, additional functional information from Gene Ontology, OMIM and homologies in other model organisms is provided. In contrast to other programs already available, which focus only on SNPs with possible effect in the protein, PupaSNP includes SNPs with possible transcriptional effect. PupaSNP will be of significant help in studies of multifactorial disorders, where the use of functional SNPs will increase the sensitivity of identification of the genes responsible for the disease. The PupaSNP web interface is accessible through http://pupasnp.bioinfo.cnio.es.10aAmino Acid Substitution Binding Sites Humans Internet Phenotype *Polymorphism10aGenetic10aSingle Nucleotide RNA Splicing *Software Transcription Factors/metabolism *Transcription1 aConde, L.1 aVaquerizas, J., M.1 aSantoyo, J.1 aAl-Shahrour, Fatima1 aRuiz-Llorente, S.1 aRobledo, M.1 aDopazo, J.  uhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15215388